IPO - Autonomix Medical, Inc.

Form Type: 10-Q

Filing Date: 2025-02-13

Corporate Action: Ipo

Type: Update

Accession Number: 000143774925003669

Filing Summary: Autonomix Medical, Inc. filed its quarterly report for the period ending December 31, 2024, as part of its continued public offerings. The report noted a significant increase in shares outstanding from 942,575 as of March 31, 2024, to 2,462,983 as of February 10, 2025, attributed to a series of capital-raising activities. The company disclosed that no liabilities were recorded on its balance sheet for outstanding options as all were out-of-the-money as of the reporting date. Additionally, the management provided updates regarding the fair value measurements based on market conditions, which included adjusting its discount rates. The operating expenses continue to grow, driven by heightened administrative costs and research expenditures.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2024-11-19

Corporate Action: Ipo

Type: New

Accession Number: 000143774924035778

Filing Summary: Autonomix Medical, Inc. has requested an acceleration of the effective date for their Registration Statement on Form S-1, filed under File No. 333-282940. The company seeks to have the statement declared effective on November 21, 2024, at 5:30 P.M. Eastern Time or as soon thereafter as possible. This request is made in accordance with Rule 461 of the Securities Act of 1933, as amended.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2024-11-19

Corporate Action: Ipo

Type: New

Accession Number: 000143774924035779

Filing Summary: On November 19, 2024, Ladenburg Thalmann & Co. Inc., representing the underwriters for Autonomix Medical, Inc.'s proposed offering, requested the U.S. Securities and Exchange Commission to accelerate the effective date of the Registration Statement on Form S-1, File No: 333-282940, to 5:30 p.m. Eastern Time on November 21, 2024. The document outlines the company's intention to ensure adequate distribution of the preliminary prospectus to underwriters and others involved in the securities distribution. The undersigned, Nicholas Stergis of Ladenburg Thalmann, affirms awareness of obligations under Rule 15c2-8 of the Securities Exchange Act of 1934 regarding delivery requirements for the offering.

Document Link: View Document